Literature DB >> 19756623

[Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches].

W Roth1.   

Abstract

Numerous data indicate that defects in apoptotic signaling pathways contribute to the development of cancer and to therapy resistance in many types of malignant tumors. Defective apoptotic cell death is not only a significant cause of cancer, but also increases tumor resistance to chemo- and radiotherapy. Therefore, there is an urgent need to elucidate the molecular basis of apoptosis resistance and to develop novel strategies to overcome this resistance. One important task is the identification of those anti-apoptotic proteins that render tumor cells resistant to therapy and to investigate how these resistance mechanisms can be regulated on a cellular and molecular level. Based on these findings, novel strategies to sensitize cancer cells to cell death induction can be developed. Moreover, the expression profiles of several apoptosis-regulating proteins can be used as prognostic factors in patients with diverse types of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756623     DOI: 10.1007/s00292-009-1181-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

1.  Apoptosis and cancer: when BAX is TRAILing away.

Authors:  Wilfried Roth; John C Reed
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 2.  Apoptosis-based therapies.

Authors:  John C Reed
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

Authors:  W Roth; S Isenmann; M Nakamura; M Platten; W Wick; P Kleihues; M Bähr; H Ohgaki; A Ashkenazi; M Weller
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

5.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 6.  Targeting death receptors in cancer with Apo2L/TRAIL.

Authors:  Sean K Kelley; Avi Ashkenazi
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

7.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Authors:  R M Pitti; S A Marsters; D A Lawrence; M Roy; F C Kischkel; P Dowd; A Huang; C J Donahue; S W Sherwood; D T Baldwin; P J Godowski; W I Wood; A L Gurney; K J Hillan; R L Cohen; A D Goddard; D Botstein; A Ashkenazi
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

8.  The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway.

Authors:  A Eckert; B C Böck; K E Tagscherer; T L Haas; K Grund; J Sykora; C Herold-Mende; V Ehemann; M Hollstein; H Chneiweiss; O D Wiestler; H Walczak; W Roth
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

9.  Functional characterisation of decoy receptor 3 in Crohn's disease.

Authors:  B Funke; F Autschbach; S Kim; F Lasitschka; U Strauch; G Rogler; G Gdynia; L Li; N Gretz; S Macher-Goeppinger; B Sido; P Schirmacher; S C Meuer; W Roth
Journal:  Gut       Date:  2008-11-27       Impact factor: 23.059

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.